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Implementing cardiovascular disease
prevention guidelines to translate
evidence-based medicine and shared
decision making into general practice:
theory-based intervention development,
qualitative piloting and quantitative
feasibility
Carissa Bonner1*, Michael Anthony Fajardo1, Jenny Doust2, Kirsten McCaffery1 and Lyndal Trevena1
Abstract
Background: The use of cardiovascular disease (CVD) prevention guidelines based on absolute risk assessment is
poor around the world, including Australia. Behavioural barriers amongst GPs and patients include capability (e.g.
difficulty communicating/understanding risk) and motivation (e.g. attitudes towards guidelines/medication). This
paper outlines the theory-based development of a website for GP guidelines, and piloting of a new risk calculator/
decision aid.
Methods: Stage 1 involved identifying evidence-based solutions using the Behaviour Change Wheel (BCW)
framework, informed by previous research involving 400 GPs and 600 patients/consumers. Stage 2 co-developed
website content with GPs. Stage 3 piloted a prototype website at a national GP conference. Stage 4 iteratively
improved the website based on “think aloud” interviews with GPs and patients. Stage 5 was a feasibility study to
evaluate potential efficacy (guidelines-based recommendations for each risk category), acceptability (intended use)
and demand (actual use over 1 month) amongst GPs (n = 98).
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Results: Stage 1 identified GPs as the target for behaviour change; the need for a new risk calculator/decision aid
linked to existing audit and feedback training; and online guidelines as a delivery format. Stage 2-4 iteratively
improved content and format based on qualitative feedback from GP and patient user testing over three rounds of
website development. Stage 5 suggested potential efficacy with improved identification of hypothetical high risk
patients (from 26 to 76%) and recommended medication (from 57 to 86%) after viewing the website (n = 42), but
prescribing to low risk patients remained similar (from 19 to 22%; n = 37). Most GPs (89%) indicated they would use
the website in the next month, and 72% reported using it again after one month (n = 98). Open feedback
identified implementation barriers including a need for integration with medical software, low health literacy
resources and pre-consultation assessment.
Conclusions: Following a theory-based development process and user co-design, the resulting intervention was
acceptable to GPs with high intentions for use, improved identification of patient risk categories and more
guidelines-based prescribing intentions for high risk but not low risk patients. The effectiveness of linking the
intervention to clinical practice more closely to address implementation barriers will be evaluated in future research.
Keywords: Cardiovascular disease, Primary care, Risk communication, Risk assessment, Behaviour change,
Evidence-based medicine, Shared decision making, Decision aids, Audit and feedback
Background
CVD prevention guidelines
Cardiovascular disease prevention guidelines around the
world recommend assessing the absolute risk of a heart at-
tack or stroke in the next 5–10 years. This is intended to
guide the use of blood pressure and cholesterol-lowering
medication for those at “high risk” [1, 2], based on the most
predictive risk factors [3]. Reviews show the absolute risk
approach can improve clinical management of CVD risk,
patients’ risk perception and patients’ preventive intentions,
compared to treating hypertension and hyperlipidaemia as
separate risk factors [4, 5]. Treatment based on high abso-
lute risk may prevent over-treatment of low-risk patients
with an isolated risk factor and under-treatment of high-
risk patients with multiple elevated risk factors [6].
The evidence-practice gap
Despite available guidelines, absolute risk is often
not assessed. When it is assessed, it is not necessar-
ily used to guide management decisions [7–10]. A
survey of 2000 clinicians across North/South Amer-
ica and Europe found less than half use absolute risk
scores regularly. Those who did not use absolute risk
were less likely to identify the need for lipid-lower-
ing medication in a hypothetical patient scenario [7].
The consequences are significant. In Australia, 75%
of high-risk patients are not receiving recommended
medication to prevent death and disability from
CVD, and 25% of low risk patients are taking medi-
cation they are unlikely to benefit from [11]. This
evidence-practice gap is estimated to cost the na-
tional health system AU$5.4 billion [12]. Interven-
tions to improve the use of absolute risk assessment
in Australia have included pre-consultation risk
assessment and integrating risk calculators with
medical software [13–15], but these interventions
had limited impact on prescribing and have not been
translated into clinical practice nationally.
Behavioural barriers
The Healthy Heart Study aimed to identify and under-
stand behavioural barriers to CVD prevention guidelines
in Australia through research with 400 GPs and 600
patients/consumers in 2011–2018 (see Table 1). This
project identified barriers not addressed in previous tri-
als, including psychological capability (lack of knowledge
about how risk factors relate to medication and lifestyle
guidelines, and difficulty understanding/explaining abso-
lute CVD risk); physical opportunity (lack of access to
updated evidence and risk communication tools that
match Australian guidelines); and reflective motivation
(concerns about how to apply guidelines to challenging
patient scenarios) [16, 17]. Two strategies have strong
evidence to address these issues: audit and feedback can
improve knowledge and motivation; and patient decision
aids improve risk perception and communication [25,
26]. Audit and feedback programs on this topic were
already available to GPs, involving audit of 10 patients
with feedback comparing performance to guidelines and
peers. There were no available tools to assist GPs with
communicating Australian absolute risk guidelines to
patients. Systematic reviews of existing online CVD risk
communication tools (73 risk calculators and 25 decision
aids) found none that met Australian guidelines, used
best practice risk communication formats, followed
international patient decision aid standards for present-
ing all management options in a balanced way or met
the needs of people with lower health literacy [23, 24].
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Aim
This study aimed to develop, pilot and evaluate the feasi-
bility of a new online platform for the Australian CVD
prevention guidelines that links existing strategies (risk
calculator, audit and feedback) with a new patient deci-
sion aid, in order to (1) help GPs identify guideline-
based recommendations for medication and lifestyle
change and (2) communicate this to patients. This paper
outlines the results of a theory-based intervention devel-
opment process, qualitative piloting and quantitative
feasibility research for the new combined risk calculator/
decision aid component that was not previously available
to Australian GPs.
Methods
The methods involved 5 different stages:
1. Intervention development based on Behaviour
Change Wheel process
2. Co-design of content with GPs
3. GP conference feedback on prototype website
4. GP and patient interview feedback on functional
website
5. Feasibility study with GPs using final website over
1 month
Ethical approval was obtained via the University of
Sydney and Royal Prince Alfred Hospital Human
Research Ethics Committees.
Setting
The project was conducted in Australia in 2017–2018,
based on national CVD prevention guidelines released in
2009 (assessment) and 2012 (management) [1, 27]. The
guidelines target General Practitioners (GPs) who can be
accessed free of charge under the Medicare system. They
are based on the 5-year Framingham model of absolute
CVD risk, with different recommendations for:
 Low risk (< 10%): no medication with lifestyle
change (smoking, diet, exercise) as needed;
 Moderate risk (10–15%): lifestyle change initially,
unless extra risk factors are present or lifestyle
change is ineffective (in which case medication
should be considered); and
 High risk (> 15%): both blood pressure/cholesterol
lowering medication and lifestyle change.
Stage 1: Intervention development based on the
Behaviour Change Wheel process
The first stage for this paper was to clearly articulate
the problem and solutions in behavioural terms, to
Table 1 Healthy Heart Study findings
Study description Implications
1 GP interviews about CVD risk assessment and management [16, 17] GPs use a range of CVD risk assessment strategies, and
identified capability (knowledge, communication) opportunity
(access, time) and motivation (habit, concerns about applicability
of guidelines to certain patients) as key barriers to absolute
risk assessment
2 Patient interviews about CVD risk assessment and management [18] Patient and GP decision making about CVD risk management
is influenced by perceived risk and attitudes rather than
calculated absolute risk of a CVD event
3 GP experiment to explore relative influence of absolute risk
vs blood pressure/cholesterol on prescribing [19]
Providing an absolute CVD risk assessment is not sufficient
to overcome GPs’ tendency to prescribe medication based
on blood pressure/cholesterol alone
4 Patient “think aloud” study using heart age calculators [20] Heart age calculators prompted emotional reactions and
consideration of lifestyle changes, but unexpected ‘older’
heart age results were not believable
5 Patient experiment testing heart age versus 5-year absolute CVD risk [21] Heart age is easier to recall but also inflates risk perception
and is less credible than 5-year absolute CVD risk, with no
advantage for lifestyle change intentions
6 Patient “think aloud” study using absolute risk calculators [22] Absolute CVD risk is more meaningful when provided alongside
a verbal description of the risk category and graphical displays
of intervention effects for both lifestyle and medication
7 Systematic review of existing CVD risk calculators [23] There were 73 CVD risk calculators available online, but none
matched Australian guidelines and they were not suitable for
people with lower health literacy
8 Systematic review of CVD decision aids [24] There were 25 CVD decision aids available online, but none
matched Australian guidelines, few presented both lifestyle
and medication options
in a balanced way, and they were not suitable
for people with lower health literacy
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address the issues identified in the Healthy Heart
Study. We used the Behaviour Change Wheel (BCW)
framework because it synthesises multiple health be-
haviour theories and models to guide the develop-
ment of rigorous interventions [28]. According to this
framework, behaviour can be attributed to three de-
terminants of behaviour: opportunity (physical and so-
cial environment), capability (physical and
psychological ability) and motivation (automatic and
reflective mechanisms). The framework outlines a
process to identify the most important behavioural
barriers, the best target population for behaviour
change, evidence-based behaviour change techniques
and the most feasible delivery mode.
Stage 2: Co-design of content with GPs
The website content was co-developed with GPs via
the ‘Ask Share Know: Rapid Evidence for General
Practice Decisions: (ASK-GP) Centre of Research Ex-
cellence Clinical Laboratory.’ This includes a ‘know-
ledge broker’ service that provides evidence-based
resources for GPs to discuss at small group meetings,
which were audio-recorded to supplement field notes
(CB and MF). Two GP groups were included as they
were running discussions at the time of the study.
Qualitative data were obtained via field notes to
document any suggested changes or problems identi-
fied by users as part of the co-design process, with
audio recordings used to clarify field notes if needed.
A summary of each group discussion was written,
and this document was scanned to identify changes
to be made for the next website version. No formal
qualitative analyses were conducted.
Stage 3: GP conference feedback on prototype website
The website prototype was piloted at an Australian na-
tional conference for General Practitioners in 2017
(GP17) via a presentation and question/answer session
(CB) and a tablet placed in an exhibition room stall
(CB). Conference data included notes from verbal
discussion with stall visitors and a brief written feedback
form from attendees with open responses and an overall
acceptability rating out of 10.
Stage 4: GP and patient interview feedback on functional
website
After the GP17 conference, the functional website was
developed iteratively based on semi-structured ‘think
aloud’ user interviews [29] to improve acceptability. A
more detailed Framework Analysis had been conducted
in 1 GP interview study and 2 patient think aloud stud-
ies prior to this stage (see Table 1), so thematic analysis
for this stage was limited to notes taken during the in-
terviews (CB and MF) and from audio recordings, to
identify areas to improve. Interviews were conducted at
the University of Sydney, via Skype or at the participants’
residence/workplace, and were audio-recorded to sup-
plement field notes on intervention features to improve.
This involved a concurrent and retrospective verbal
protocol where users were asked to think aloud as they
used the website, followed by prompting for feedback by
the interviewer (CB) [20].
Stage 5: Feasibility study with GPs using final website
over 1month
A feasibility study to assess acceptability (intended
use after initial viewing), demand (actual use after 1
month) and potential efficacy (improved knowledge of
recommended interventions for each risk category as
per guidelines) [30] was conducted for the final web-
site. A pre-post design was used to maximise feed-
back from ~ 100 end users within the project budget,
with oversampling at baseline (n = 123) to achieve
adequate numbers at follow-up (n = 98). GPs were
recruited anonymously via an independent recruit-
ment company, which could not provide identifying
information about GPs; therefore, it is unknown
whether (if any) overlap occurred with the GPs par-
ticipating in the qualitative stages. The 10-min base-
line survey is provided in Additional file 2 and
included use of guidelines and absolute CVD risk cal-
culators; self-efficacy for assessing and communicating
absolute CVD risk [31]; testing one of 9 hypothetical
patients (3 each from low, moderate and high risk
categories as per Australian guidelines) with the web-
site to explore whether recommendations matched
risk category guidelines for challenging cases [16, 17];
intended use of website features over the next month;
open feedback; and demographics. The 4-min follow-
up survey was sent in 3 batches 1 month after com-
pletion of the baseline survey to standardise the fol-
low-up period (range 4–6 weeks). It repeated the
same questions without the hypothetical patient test-
ing or demographics, with self-reported website usage
assessed for the previous month. GPs participated
anonymously via a specialist recruitment company
and received $40 along with access to a login and
pre-filled form to apply for continuing professional
development points if they chose to complete the
self-directed audit and feedback component of the
website. Descriptive analyses and confidence interval
calculations were conducted using Microsoft Excel,
and inferential analyses were conducted using SPSS
v25. Chi-squared tests and paired t tests were used to
compare categorical data and continuous data, re-
spectively, between baseline and follow-up. Only the
final sample of 98 was used in the analysis.
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Results
Stage 1: Intervention development based on Behaviour
Change Wheel process
Completing the Behaviour Change Wheel process (sum-
marised in Table 2) identified the need to develop a new
tool for GPs to use with their patients in consultations,
with the following key features (see Figs. 1, 2 and 3 for
screenshots of main features, and Additional files 1 and 2
for TIDIER checklist and more detailed intervention
content):
1. Interactive CVD risk calculator that combines CVD
risk assessment and management algorithms to help
GPs identify risk category guidelines [1, 27], based
on best practice risk communication principles and
patient perceptions of existing CVD risk calculators
[20, 22, 32];
2. Personalised patient decision aid that shows the
effect of different medication (blood pressure,
cholesterol, aspirin), lifestyle (smoking, diet,
exercise) and supplement (antioxidants, omega-3,
multivitamins) interventions on individual CVD risk
to help GPs discuss the benefits and harms of
different options [26], based on updated evidence
reviews and International Patient Decision Aid
Standards to support shared decision making [33];
and
3. Self-directed audit & feedback including cases that
GPs find challenging for CVD risk assessment and
communication [16, 17], and comparison of
management to guidelines [27], using evidence-
based behaviour change techniques [34], based on
existing audit and feedback tools familiar to GPs
(involving audit of 10 patients with feedback
comparing performance to guidelines and peers).
In terms of the BCW framework [28], the intervention
targets GPs during consultations and uses education,
training and persuasion functions to address psychological
capability (decision aid to improve knowledge of applic-
able guidelines and communication skills; supported by
audit and feedback), physical opportunity (by providing
the first CVD prevention decision aid based on Australian
guidelines and updated evidence) and reflective motiv-
ation (by addressing GP concerns through case studies
that show how absolute risk can be assessed and commu-
nicated; linked to decision aid and part of audit and feed-
back). It uses multiple behaviour change techniques
(information about health consequences, feedback on
behaviour, instruction on how to perform a behaviour,
action planning, social comparison) delivered via the
policy category of guidelines, using an online format for
wide accessibility and flexible/sustainable implementation,
see Table 2.
Stage 2–4: Qualitative piloting of content, prototype
website and functional website
Table 3 shows how iterative user feedback led to
changes to the website over stages 2–4.
Stage 2: Co-design of content with GPs
The website content and format was discussed with two
practices involved in the ASK-GP CRE (n = 18 GPs),
including feedback on examples of evidence summaries,
decision aids and CVD risk calculators. Changes were
made to the evidence summaries to incorporate more
practical issues such as cost and inconvenience to pa-
tients. GPs asked about complementary and alternative
medicine options (fish oil, antioxidants and multivita-
mins), which were subsequently included in the risk cal-
culator/decision aid even though they had no effect on
CVD outcomes, as the GPs felt it would be helpful to
show this to patients in order to direct them to more
effective options.
Stage 3: GP conference feedback on prototype website
The prototype website was demonstrated at the national
GP17 conference in October 2017 via a 30-min
Table 2 Summary of conclusions from the Behaviour Change Wheel framework process
Intervention
functions
Behavioural components
served by intervention functions
Behaviour change
techniques (BCTs) to
deliver intervention
functions
Policy categories
through which
BCTs can be
delivered
Intervention strategy
• Education
• Training
• Persuasion
• Psychological capability
(understanding role of risk factors, risk
communication) [16, 17]
• Physical opportunity (access to
updated evidence on risk/benefit in
line with Australian guidelines) [16, 23,
24]
• Reflective motivation (attitude towards
using guidelines for perceived low/
high risk cases) [16]
• Information about
health consequences
• Feedback on behaviour
• Instruction on how to
perform a behaviour
• Action planning
• Social comparison
• Guidelines Online version of guidelines to enable
national access, linked to:
• 5-year risk calculator that integrates
assessment and management guidelines
including clear role of risk factors
• Updated evidence on benefits and harms
for medication + lifestyle options
• Decision aid for patients to improve
communication
• Hypothetical patient cases with feedback
as part of audit and feedback training
exercise [based on existing resources]
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Fig. 1 Patient risk calculator and decision aid
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Fig. 2 GP audit and feedback exercise
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presentation with a question/answer session (attended
by n = 113 delegates) and a conference stall where 25
GPs tested the prototype website on a tablet, of which
16 completed a written feedback form. Verbal and writ-
ten feedback was positive, with an average 8.4/10 overall
acceptability rating and comments such as: “So user
friendly, takes relevant clinical data into account, very
comprehensive recommendations which are patient as
well as doctor friendly”.
Stage 4: GP and patient interview feedback on functional
website
In-depth user feedback was obtained from 7 GPs via
ASK-GP CRE groups and interested GP17 conference
attendees, using semi-structured “think aloud” interviews
while using the preliminary website. Suggestions include
risk factor and intervention wording changes, automatic
calculation of risky drinking and body mass index, and
changes to the visual presentation of the risk result to
enable black and white printing. These changes were in-
corporated into the website before further testing with 3
new GPs and 9 patients. Another round of changes was
made for the final website halfway through this testing,
including a two-page summary of a single intervention
as well as the full decision aid. No major content issues
were identified in final website testing, but there were
some suggestions for implementation to improve acces-
sibility: linking the risk calculator to GP practice soft-
ware, involving practice nurses and creating a patient/
consumer version of the website that is easier to under-
stand without GP consultation. These issues could not
be addressed within the project budget for intervention
development. The final website is available at www.
auscvdrisk.com.au.
Stage 5: Feasibility study with GPs using final website
over 1month
Tables 4 and 5 provide an overview of the sample and
descriptive capability results before and after using the
risk calculator/decision aid component of the website.
Sample description
The participant characteristics are summarised in
Table 4. At baseline, almost all (95%, n = 93)
reported using absolute CVD risk calculators, most
commonly risk calculators within practice software
(Best Practice 35%, n = 34; Medical Director 21%, n = 21)
and the National Vascular Disease Prevention Alliance
website (www.cvdcheck.org.au; 32%, n = 31). A lower pro-
portion (72%, n = 71) of GPs had seen the national CVD
prevention guidelines.
Potential efficacy (guideline-based recommendation for risk
category)
At baseline, using the new decision aid at www.auscvdrisk.
com.au with a self-selected hypothetical patient signifi-
cantly increased identification of the correct risk category
for low risk cases by 16% (95% CI 0 to 32%), moderate risk
Fig. 3 Summary of intervention development and testing
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cases by 32% (95% CI 6 to 57%) and high risk cases by
50% (95% CI 35 to 65%); and increased identification of
blood pressure and/or cholesterol medication as a recom-
mendation for high risk (see Fig. 4 and Table 5). From 42
GPs who selected a high-risk case, 57% (n = 24) were
likely/very likely to prescribe medication. After using the
risk calculator, 86% (n = 36) indicated blood pressure
or cholesterol medication were recommended, and 69%
(n = 29) indicated both were recommended. From 37 GPs
who selected a low-risk case, prescribing was similar be-
fore (19%, n = 7) and after (22%, n = 8) using the risk
calculator.
Acceptability (intended use)
At baseline, most GPs (88%, n = 86) intended to use the
website (at least 1 feature) over the next month.
Table 3 Website development based on iterative user feedback
Development stage Example user feedback Major changes made
Stage 1: Intervention
development based on
Behaviour Change Wheel process
Healthy Heart Study GP interview: ‘The calculator of
course doesn’t include certain factors…if someone does
do a lot of exercise I would…think their risk is probably
lower.’ [16]
Healthy Heart Study patient interview: ‘The visual
presentation of the result…because it’s a picture instead
of numeric, I think I’ll take more interest…when you see
red and green…that seems to have more of a impact
on me, you know…the numbers don’t, you know?’ [22]
• Develop new risk calculator to more clearly explain
risk factor roles in assessment versus management
guidelines (psychological capability), supported by
links to existing audit and feedback strategies
(reflective motivation)
• Link risk calculator to patient decision aid with colour
coded icon arrays to help GPs explain probability of
CVD event to patients (psychological capability) and
access up-to-date intervention effects on their risk
(physical opportunity)
Stage 2: Co-design of content
with GPs
GP focus group: “Is it possible you need to quote
something along the lines of ‘no evidence regarding
dose or exact dose’ or something? Cos patients ask you
a lot of ‘how much should I take?’… It could be good
with a bit of extra information and a little bit more
about the doses and the side effects and costs and so
on”
• Less statistical information and more practical issues
for GP evidence summaries
• Include complementary and alternative medicine
options to show lack of effect on CVD outcomes
Stage 3: GP conference feedback
on prototype website
GP conference feedback: ‘Improved diet’ is very vague
and after all, the benefit is only with the Mediterranean
diet and has not been shown with other ‘improved
diets’.
GP interview: ‘So are there explanations…for alcohol,
you want to put what moderate means...it’s not going to
calculate BMI for you?’
• Rewording risk factors and interventions to be clearer
• Automatic calculation of body mass index and risky
drinking
• Changed icon array shades to cater to vision
impairments and black/white printing
Stage 4a: GP and patient
interview feedback on functional
website
GP interview: ‘It’s directed towards the risk factor they’ve
actually identified?... I think this is really good the
summary… it’s really comprehensive…let’s not waste
any time talking at length about smoking if you’re not
even considering it…whereas what about your diet…
oh yes I’m keen to know about that’
Patient interview: ‘With the button where it says print…
it automatically comes up with the print page ahead of
viewing it, so maybe it’s better to view it first and have
the option to print later so you don’t have to print it’
• Add print button for 2 page summary of single
intervention selected by GP
• View decision aid information in separate tab before
printing
• Change summary table in full 9 option decision aid
to more clearly show effects on risk
Stage 4b: GP and patient
interview feedback on final
website at www.auscvdrisk.com.
au
GP interview: ‘The patient would be given an ipad…give
it to the nurse or hand it back to reception…doing the
AUSDIAB [diabetes risk assessment] at reception was
really good…enter it on the patient file…if it was high
then I would need know’
Patient interview: ‘I have to talk to the doctor about the
cholesterol lowering medication, and blood pressure
and aspirin…I can take this [decision aid] with me next
time I go to see her’
• No further changes made to GP website or linked
resources
• Implementation suggestions still need to be
addressed:
1. Auto-population of risk factors from patients’
electronic record;
2. Low health literacy version of decision aid;
3. Pre-consultation access to risk calculator/decision aid
Stage 5: Feasibility study with
GPs using final website over 1
month
GP open response comments reflecting key
implementation issues:
‘If it could be somehow linked to practice software so I
remember to do it and the values are prefilled that
would be ideal.’
‘Needs to have some in different languages to show
people outcomes for those with poor English
understanding.’
‘More time to be scheduled to counsel patients on
lifestyle modification and CVD risk calculator use.’
• Feedback generally positive with some contrasting
views on format preferences
• Confirmed implementation issues identified in stage
4b:
1. Auto-population of risk factors from patients’
electronic record
2. Low health literacy version of decision aid;
3. Pre-consultation access to risk calculator/decision aid
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Demand (actual use over 1 month)
At 1-month follow-up, most GPs (73%, n = 72) re-
ported using the website (at least 1 feature) in the
last month. This included interactive risk calculator
features (73%, n = 72), printed decision aid features
(67%, n = 66) and guideline features (52%, n = 51).
Other outcomes
At 1-month follow-up, there were no significant pre-post
differences in reported use of absolute risk assessments;
self-efficacy in conducting an absolute CVD risk assess-
ment; or self-efficacy in explaining absolute CVD risk.
Open feedback
In open feedback, improvements were suggested by 44%
(n = 43) and 40% (n = 39) of GPs at baseline and follow-
up, respectively. Of all suggested improvements at base-
line, improving access (e.g. via Practice Software
integration) was most common (48%, n = 21) followed
by formatting changes (29%, n = 13; e.g. colour and font)
and content changes (23%, n = 10; e.g. more instruc-
tions, different website design features, additional risk
factor/effect estimates beyond the scope of the guide-
lines). Similarly, of all suggested improvements at fol-
low-up, improving formatting was most common (58%,
n = 23) followed by improving access (40%, n = 41) and
content changes (20%, n = 8).
Discussion
This paper outlines a rigorous theory-based process to
develop an intervention to improve the use of guidelines
for CVD prevention in Australia, aiming to address GP
barriers. It draws on the large literature supporting the
use of audit and feedback to change GP prescribing be-
haviour and use of guidelines, and patient decision aids
to improve doctor-patient communication and under-
standing of risk [25, 26]. It also adds to the growing use
of the Behaviour Change Wheel framework for develop-
ing public health interventions to diagnose and target
behavioural barriers to public health [28]. From the Be-
haviour Change Wheel Framework, the education, train-
ing and persuasion functions to address psychological
capability, physical opportunity and reflective motivation
components collectively increased the capacity for GPs
to correctly identify CVD risk categories for several sce-
narios. Improvement in intentions to prescribe to high-
risk patients was also observed, although there was little
change to prescribing to low-risk patients. Use over 1
month and intentions for future use were high suggest-
ing acceptability to end users.
However, we know that both evidence-based medicine
and shared decision making face many barriers more
broadly, including environmental and system level issues
[35]. The pilot findings suggest several directions for im-
plementation that have already been trialled in the Aus-
tralian primary care context, which may be effective if
Table 4 Feasibility study participant characteristics
Characteristics Final sample (n = 98)
Age (mean) 52.6 years (SD 8.57)
Experience as GP (mean) 28.0 years (SD 8.98)
Gender
Male 67 (68%)
Female 30 (31%)
Other/prefer not to say 1 (1%)
Australian state/territory
New South Wales 31 (32%)
Victoria 28 (29%)
Queensland 22 (22%)
Western Australia 4 (4%)
Tasmania 2 (2%)
Northern Territory 1 (1%)
Australian Capital Territory 1 (1%)
Table 5 Correct risk category and medication recommendation before and after using the website
Selected case Before using risk calculator After using risk calculator
Low risk (n = 37) Correct risk category: 70% Correct risk category: 87%
Likely/very likely to prescribe
any meds: 19%
Blood pressure med recommended: 22%
Cholesterol med recommended: 22%
Moderate risk (n = 19) Correct risk category: 58% Correct risk category: 90%
Likely/very likely to prescribe
any meds: 74%
Blood pressure med recommended: 32%
Cholesterol med recommended: 42%
High risk (n = 42) Correct risk category: 26% Correct risk category: 76%
Likely/very likely to prescribe
any meds: 57%
Blood pressure med recommended: 71%
Cholesterol med recommended: 83%
Note: see Additional file 1 for details of the 9 hypothetical patient cases (3 per risk category; randomised order in survey and also presented in the audit and
feedback section of website; developed from Healthy Heart Study GP interviews that identified situations where absolute risk assessment/communication is most
challenging [16, 17])
Bonner et al. Implementation Science           (2019) 14:86 Page 10 of 14
combined with the existing intervention. Specifically,
there are three suggestions from GPs and patients in this
study that still need to be addressed (see Table 1):
1. Pre-consultation access to risk calculator/decision
aid: Both GPs and patients suggested that the risk
assessment and decision aid could be accessed prior
to a consultation before further discussion, ideally
with the support of practice nurses and a more
consumer-friendly interface. This method has been
trialled previously in Australia for CVD risk
assessment using a waiting room method [15], but
without the additional support of a risk calculator/
decision aid that addressed capability barriers
around understanding and communication of risk
models. Existing risk calculators did not explain the
role of assessment vs management factors, and no
decision aids were available that matched 5-year
Australian CVD risk guidelines.
2. Auto-population of risk factors from patients’
electronic record: This was a suggestion from GPs,
who wanted to save time by having the risk
assessment linked to patients’ recorded risk factors
in medical software. This approach has been trialled
previously in Australia [13, 14], but access to the
risk calculator was restricted to license holders and
did not have the additional support of a decision aid
to address communication of risk models. Existing
tools were inaccessible or did not match Australian
guidelines.
3. Low health literacy version of decision aid to meet
the needs of people with inadequate skills to access,
understand and act on health information. This was
suggested by GPs working with diverse
communities, who felt the full decision aid with 9
options would be too much information for many
of their patients. Low health literacy decision aids
have been developed and trialled in Australia using
a “universal precautions” approach to health-literate
design, but not for CVD prevention [36].
The next stage of the project will use a combination of
the above strategies to support the implementation and
evaluation of the intervention in clinical practice, as well
as aligning with national Heart Foundation programs
that aim to improve the use of absolute CVD risk assess-
ment and communication about management options
with patients in primary care. The implementation of
tools to support shared decision making and health liter-
acy is timely in Australia, with recent policy changes ex-
plicitly supporting these two areas [37]. Internationally,
there have been calls to use shared decision making in
relation to changing CVD prevention guidelines in the
UK and US, given lower medication thresholds that may
result in many previously ‘low risk’ patients taking medi-
cation for very small benefits in risk reduction [38–40].
Additional strategies may be needed to address the over-
treatment of low risk patients, since little change was ob-
served in this study.
Implications for implementation science
Our results highlight a theoretical issue regarding the
difference between implementation (prescribing for high
risk) and de-implementation (not prescribing for low
risk) [41]. While addressing capability barriers to guide-
lines appeared to increase intentions for prescribing
medication to high-risk patients, there was no improve-
ment in unnecessary prescribing for low risk patients. A
recent synthesis of behaviour change theory suggests
that behaviour substitution may be needed to address
Fig. 4 Correct identification of risk category for low, moderate and high risk patient cases
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the latter situation, but there is little guidance in the lit-
erature for how to select such a behaviour at present
[41]. More broadly, this project provides a model to
other intervention developers for how to apply the the-
ory-based Behaviour Change Wheel framework to iden-
tify behavioural barriers to the use of guidelines [28],
and co-design an evidence-based intervention with end
users to address these barriers. In particular, it illustrates
the value of an extensive qualitative evaluation to under-
stand behavioural barriers amongst different targets
(GPs and patients) and testing different strategies/for-
mats before trialling an evidence-based intervention, as
previous trials in this context had little impact on pre-
scribing and failed to incorporate important knowledge
(confusion about the role of different risk factors) and
capability (doctor-patient risk communication) issues.
The iterative co-design process for website development
shows how GP and patient feedback can be incorporated
into intervention design, but the timeframe required for
this process meant that the qualitative analysis was prag-
matic rather than formally thematic. Future intervention
designers may benefit from: (1) considering implementa-
tion and de-implementation components separately as
different behavioural strategies may be needed and (2)
long-term planning to allow time for detailed explor-
ation of behavioural barriers initially and more in-depth
analysis of purposively sampled user feedback during
development.
Strengths and limitations
This paper highlights the usefulness of mixed qualitative
and quantitative methods to understand the context and
behavioural barriers to a public health issue, and an it-
erative user feedback process to develop the interven-
tion. The resulting intervention is evidence-based and
acceptable to users in Australia, but needs further testing
to evaluate its efficacy and use in clinical practice. The
main limitations are (1) the use of pragmatic qualitative
analysis methods (i.e. documenting issues in field notes/
summary documents to facilitate quick feedback to web-
site developers rather than formal thematic analysis); (2)
the use of a pre-post design to maximise end user feed-
back, rather than a randomised trial design; and (3) the
use of GP self-report rather than GP-patient interactions
within a consultation. Future research will focus on ad-
dressing these limitations and the implementation sug-
gestions identified in the pilot study.
Conclusions
Following a theory-based development process and user
co-design, the resulting intervention was acceptable to
GPs with high intentions for use, improved identification
of patient risk categories and some improvement in
intended prescribing for high-risk but not low-risk
patients. The effectiveness of linking the intervention to
clinical practice more closely to address implementation
barriers will be evaluated in future research.
Additional files
Additional file 1: Components of the Australian CVD guidelines
intervention. (DOCX 2701 kb)
Additional file 2: GP survey about cardiovascular disease (CVD)
prevention guidelines. (PDF 60 kb)
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